Effect of Cabergoline on Weight and Glucose Tolerance

Completed · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Body Weight, Impaired Glucose Tolerance in Obese

In brief

The aim of this study is to determine the efficacy of cabergoline, a long-acting dopamine receptor agonist, on body weight and blood glucose in healthy obese adults. This is a randomized double-blind placebo controlled study. Twenty subjects each will be randomly assigned either placebo or cabergoline for 16 weeks. The effect of treatment on body weight and blood glucose and insulin levels will be compared in the treatment versus the placebo arm.

Key facts

Study ID

NCT01395602

Run by

Columbia University

People needed

40

Starts

2002-04-01

Expected to finish

2011-07-01

Last updated by the study team

2015-10-14

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• age 18 - 55 years
• BMI 30 -40

You may not qualify if…

• diabetes,
• clinically significant medical condition,
• use of medications that effect blood glucose or body weight

Where it is running

• Columbia University — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.